Merck

Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer

Retrieved on: 
Wednesday, March 22, 2023
Filippo Jacobio, CD73, Trial of the century, Patient, Merck, Merck & Co., Pembrolizumab, Merck Sharp & Dohme Federal Credit Union, Immunosuppression, Tumor microenvironment, Pharmaceutical industry

BEIJING, SHANGHAI and BOSTON, March 22, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combination of Jacobio's CD73 monoclonal antibody JAB-BX102 in combination with Merck & Co., Inc., Rahway, NJ, USA's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

Key Points: 
  • BEIJING, SHANGHAI and BOSTON, March 22, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combination of Jacobio's CD73 monoclonal antibody JAB-BX102 in combination with Merck & Co., Inc., Rahway, NJ, USA's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).
  • The clinical study will evaluate the clinical effect of JAB-BX102 in combination with KEYTRUDA for the treatment of advanced solid tumors.
  • "The CD73 monoclonal antibody is Jacobio's first large molecule project to enter the clinic.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

CHC and Merck partner to advance more equitable health outcomes in breast and cervical cancer care in Black, Hispanic, and other underserved populations

Retrieved on: 
Tuesday, March 21, 2023
MSD, DNA, CHC, Partnership, Breast cancer, Health equity, Cancer, Woman, Breast, Incidence, Trust, Cervical cancer, AVP, Risk, Biophysical environment, Diagnosis, ESG, Health, Death, Birth control, Nursing, Black, Merck

ALEXANDRIA, Va., March 21, 2023 /PRNewswire-PRWeb/ -- Today, CHC: Creating Healthier Communities (CHC) announced a new initiative to tackle social and structural barriers to breast and cervical cancer prevention, screening, and support services in Atlanta, Georgia. Through a partnership with Merck (known as MSD outside the United States and Canada), women and girls in the Black, Hispanic and other underserved populations will benefit from a comprehensive, community-driven service approach to address complex social and economic factors, known as social determinants of health.

Key Points: 
  • "We're working together to address disparities by identifying and targeting barriers to early and routine breast and cervical cancer screenings—a proven intervention that can save lives," said Valerie L. Rochester, chief health equity officer at CHC.
  • Breast cancer and cervical cancer incidence in the U.S. has increased steadily over the past ten years with a disproportionate impact on underserved communities.
  • This new program will enhance community-based organizations' capacity to scale testing, screening and impact with the end goal to improve health outcomes for breast, cervical, and vaccine-preventable cancers.
  • Learn more equitable cancer outcomes or CHC's other health equity work .

AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues

Retrieved on: 
Tuesday, March 21, 2023
Amazon Web Services, 3D, Research, AstraZeneca, Proteomics, AION, Protein, BioMed Central, Invention, Merck, AI, AWS, Pharmaceutical industry, Video game, Teva, Pfizer

REHOVOT, Israel and HEIDELBERG, Germany, March 21, 2023 /PRNewswire/ --  AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced today the launch of its first 2023 global call for applications to identify technological and biomedical scientists and inventors to form a new startup at AION Labs' headquarters in Rehovot, Israel.

Key Points: 
  • AION Labs' fifth startup will focus on the development of an AI platform that identifies naturally occurring protein of interest-E3 interacting pairs that work together in specific parts of the body under specific conditions.
  • It is also looking to model the 3D structure of the interacting complex to enable small molecule design.
  • As part of the online application procedure, interested candidates are requested to submit a competitive project proposal via the BioMed X Career Space at https://career.bio.mx/call/2023-AIL-C05 before May 7, 2023.
  • Further details about this call for application can be found on the AION Labs website: www.aionlabs.com .

Bruno Rossi joins Olink as Chief Commercial Officer

Retrieved on: 
Tuesday, March 21, 2023
Leica Microsystems, Organic chemistry, Marketing, Danaher, Merck Group, CCO, Proteomics, Sales operations, Bruno, Growth, Merck, Management, Millipore

UPPSALA, Sweden, March 21, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the appointment of life sciences industry veteran Bruno Rossi to the role of Chief Commercial Officer (CCO), effective immediately.

Key Points: 
  • UPPSALA, Sweden, March 21, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the appointment of life sciences industry veteran Bruno Rossi to the role of Chief Commercial Officer (CCO), effective immediately.
  • Mr. Rossi will lead the Company’s global commercial organization including Sales, Marketing and Sales Operations.
  • “I am delighted to welcome Bruno to the Olink organization, and look forward to the value his considerable industry experience will add to our rapidly growing company.” said Carl Raimond, President of Olink.
  • “With its best-in-class technology, leading commercial organization, and tremendous talent, Olink has positioned itself as a major force within the next-generation proteomics market,” said Bruno Rossi, CCO of Olink.

Cytovation appoints Iman Barilero as Chief Development Officer

Retrieved on: 
Tuesday, March 21, 2023
Antigen, Doctor of Pharmacy, Drug development, University, Tufts Center for the Study of Drug Development, Roche, Big Pharma, Cancer, Bristol Myers Squibb, Doctor of Philosophy, CNS, Institut Gustave Roussy, MD, Central nervous system disease, Immune system, Sanofi, Merck, Merck & Co., Pembrolizumab, Pharmacology, Merck Sharp & Dohme Federal Credit Union, Pharmaceutical industry

Bergen, Norway, 21 March 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces that Dr. Iman Barilero has joined the company as Chief Development Officer.

Key Points: 
  • Bergen, Norway, 21 March 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces that Dr. Iman Barilero has joined the company as Chief Development Officer.
  • Dr. Barilero brings three decades of experience as a strategic executive in the global healthcare industry, successfully designing innovative and integrated patient-centric and value-based regulatory development pathways, in all phases of drug development and across all major global pharmaceutical markets.
  • Lars Prestegarden, MD, PhD, CEO of Cytovation, commented: “We’re delighted to have someone with Iman’s wealth of experience join Cytovation as we progress CyPep-1 through clinical development.
  • Iman has worked across Big Pharma and biotech, and her support will be invaluable as the company enters its important next stages of development and growth.”
    Iman Barilero, PharmD, PhD, Cytovation’s Chief Development Officer, added: “CyPep-1 represents an exciting new approach to cancer immunotherapy, and it’s great to be joining Cytovation at a time when the asset has such strong clinical momentum backed by promising early data.

Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer

Retrieved on: 
Monday, March 20, 2023
Columbia University, PTC Therapeutics, Drug development, Duchenne muscular dystrophy, University, Gene, Cell therapy, PTC, Gene editing, CMO, RNA, Sympathetic nervous system, Duchenne, Marketing, Human genetics, American Society of Human Genetics, Genetics, Publication, Patient, Ophthalmology, MAA, Rare, European Society for Primary Immunodeficiencies, Amicus Therapeutics, FDA, Therapy, Fabry disease, IND, Society, DSM-IV codes, Disease, Pharmaceutical industry, Medical device, EU, Ascidiacea, Merck

BOSTON, March 20, 2023 /PRNewswire/ -- Ascidian Therapeutics , a biotechnology company focused on treating human diseases by rewriting RNA, announced today the appointment of Jay A. Barth, M.D., as Chief Medical Officer (CMO).

Key Points: 
  • BOSTON, March 20, 2023 /PRNewswire/ -- Ascidian Therapeutics , a biotechnology company focused on treating human diseases by rewriting RNA, announced today the appointment of Jay A. Barth, M.D., as Chief Medical Officer (CMO).
  • "Jay's deep knowledge and experience in gene therapy and complex indications will make an immense impact for patients and for Ascidian, as we advance our exon editing therapies addressing the underlying causes of disease," said Romesh Subramanian, Ph.D., President and Chief Executive Officer of Ascidian Therapeutics.
  • We're thrilled to welcome Jay to Ascidian."
  • Immediately prior to joining Ascidian, Dr. Barth served as CMO for Lexeo Therapeutics, a clinical-stage gene therapy company focused on addressing cardiovascular and central nervous system diseases.

SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 16, 2023
MSD, Multiple myeloma, CDK9, Advanced Materials and Processes Research Institute, MPM, Clinical trial, Financial toxicity, Neoplasm, Acquisition, Lymphoma, Merck & Co., Venetoclax, Acute myeloid leukemia, GPS, Doctor of Science, WT1, NCI, Merck, MYC, Research, Mesothelioma, PD, CR2, MD, Medication, Biomarker, Patient, Protocol, Bristol Myers Squibb, Bone marrow, SLS, D, National Cancer Institute, Azacitidine, Merck Sharp & Dohme Federal Credit Union, Ovarian cancer, AML, Pharmacokinetics, IND, Nivolumab, Cryptocurrency, Pharmaceutical industry, Greater China

NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the full year ended December 31, 2022 and provided a business update.

Key Points: 
  • This participation will trigger milestone payments totaling $13 million to SELLAS, which are expected during the first half of 2023.
  • Patient enrollment was completed at the end of 2022 and SELLAS expects to report topline data during the first half of 2023.
  • Opdivo® is a registered trademark of Bristol-Myers Squibb Company, New York, NY, USA and is not a trademark of SELLAS.
  • The manufacturers of these brands are not affiliated with and do not endorse SELLAS or its products.

Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Thursday, March 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Progression-free survival, Cancer, Lung cancer, Blood, NYSE, Pembrolizumab, MRK, PFS, Patient, Merck & Co., Melanoma, Standard of care, NSCLC, Docetaxel, Immunotherapy, Safety, Lung, Pharmaceutical industry, Merck

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided an update on the open-label arm of the non-registrational Phase 2 KeyVibe-002 trial.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided an update on the open-label arm of the non-registrational Phase 2 KeyVibe-002 trial.
  • The safety profile of MK-7684A was consistent with that observed for vibostolimab and pembrolizumab in previously reported studies, with no new safety signals observed.
  • Merck has an extensive clinical development program evaluating the safety and efficacy of MK-7684A alone and in combination with other agents in over 4,000 patients.
  • Ongoing Phase 3 studies in lung cancer include KeyVibe-003 , KeyVibe-006 , KeyVibe-007 and KeyVibe-008 , as well as KeyVibe-010 in melanoma.

Transgene: 2022 Full-year Results and Business Update

Retrieved on: 
Thursday, March 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Progression-free survival, Cancer, Lung cancer, Virus, DNA, Vaccine, NCT, Euronext Paris, Conditional sentence, Pembrolizumab, AstraZeneca, Potyvirus, Neck, PFS, Neoplasm, Head, Death, Phase, IDMC, Patient, Toxicity, Merck & Co., Safety, Clinical trial, IV, Part, Circulating tumor DNA, Merck, PARP, Pharmaceutical industry, TG4050, Transgene

Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for 2022 and provides an update on its product pipeline.

Key Points: 
  • Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for 2022 and provides an update on its product pipeline.
  • I am confident that Transgene is at the forefront of helping to realize the potential of these exciting treatment modalities.
  • Transgene anticipates the last patient to be randomized in the trial in the first half of 2024, and final results to be communicated in 2024.
  • A clinical collaboration and supply agreement for KEYTRUDA® (pembrolizumab) was signed with MSD (Merck & Co) at the end of June 2022.

Major Companies Pledge to Help Afghan Refugees Advance Their Careers with Support of U.S. Military Veterans

Retrieved on: 
Thursday, March 16, 2023
Research, Workforce, Bain & Company, LGBTQ, Micrometre, SAP, Erg, Cisco, Starbucks, Woman, Employment, HelloFresh, Hilton, Veterans' affairs, CRG, LIRS, Shoulder, Mentorship, Mental health, Merck, ISS, Carpet, American Airlines, Pfizer, Sodexo, Tent, Veteran, Refugee, Chobani, Afghan

NEW YORK, March 16, 2023 /PRNewswire/ -- Today, the Tent Partnership for Refugees (Tent) announced a new initiative alongside Hiring Our Heroes and the Afghan-American Foundation to help Afghan refugees in the United States enter the workforce and advance in their careers. The program will enlist military veterans employed at participating U.S. companies – including through their veterans employee resource groups (ERGs) – to serve as mentors, with the goal of providing mentorship to at least 1,500 Afghan refugees over the next three years.

Key Points: 
  • The program will enlist military veterans employed at participating U.S. companies – including through their veterans employee resource groups (ERGs) – to serve as mentors, with the goal of providing mentorship to at least 1,500 Afghan refugees over the next three years.
  • Each company will mentor 50 Afghan refugees or more over three years, collectively reaching at least 800 of the initiative's 1,500 goal.
  • I encourage many more American companies to join this effort, especially those at the forefront of employing our nation's Veterans."
  • Companies interested in joining the Afghan Refugee Mentorship Initiative in the U.S. can find out more by emailing [email protected] .